DURHAM, N.C., Jan. 2, 2015 /PRNewswire/ -- Scioderm, Inc., today announced Robert Ryan, Ph.D., president and chief executive officer, will present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST (1:00 p.m. EST), Monday, January 12, 2015 in the Elizabethan C/D room of the Westin St. Francis hotel.
Dr. Ryan will discuss the company's lead investigational therapy, ZorblisaTM (SD-101), including data from the recently completed Phase 2b clinical trial and plans for the upcoming Phase 3 clinical trial. Zorblisa is currently in late stage development for the treatment of skin blistering and lesions associated with Epidermolysis Bullosa (EB), a rare orphan pediatric disease. Scioderm, Inc., recently announced it raised $20 million in a Series B financing round led by Redmile Group. The proceeds will be used to fund the development of Zorblisa through completion of the US and EU clinical registration programs.
About ZorblisaTM (SD-101)
Zorblisa is a proprietary topical therapy being developed for the treatment of all patients with EB. Scioderm recently completed a successful Phase 2 study SD-003 study in EB patients, which was a double-blind, randomized, placebo-controlled, dose-response trial evaluating the efficacy and safety of different dosage strengths of Zorblisa. The data showed acceleration in wound healing and closure of chronic wounds. Scioderm received Breakthrough Therapy designation for Zorblisa from the FDA, as well as orphan drug designation from the FDA and EMA.
About Epidermolysis Bullosa (EB)
Epidermolysis bullosa (EB) is a rare genetic disease leading to fragile skin susceptible to blistering and tearing. EB is chronic, debilitating and potentially disfiguring and patients with EB have painful blisters affecting a substantial percentage of their bodies that can lead to infection and scarring. There is currently no effective or FDA approved treatment for EB. Current standard of care consists solely of bandaging and bathing the open wounds to prevent infection and trying to manage patients' pain.
About Scioderm, Inc.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. Scioderm was selected as a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. The company is headquartered in Durham, North Carolina. Additional information about Scioderm can be found at www.sderm.com.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.
Scioderm Investor Contact:
Chief Executive Officer
Scioderm Media Contacts:
Andrea Flynn, Ph.D.
Russo Partners LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scioderm-to-present-at-33rd-annual-jp-morgan-healthcare-conference-300014687.html
SOURCE Scioderm, Inc.